Experimental brain cancer therapy targets tumors directly
Disease control
Not yet recruiting
This study tests a new treatment called MT027 for people with recurrent glioblastoma, an aggressive brain cancer. MT027 uses specially engineered immune cells (UCAR-T cells) that are injected directly into the fluid around the brain. The trial will include 40 adults aged 18-70 an…
Phase: PHASE2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC